Abstract
Brain natriuretic peptide (BNP) and its inactive N-terminal fragment (NT-proBNP) are strong prognostic markers in patients with manifest heart failure and acute coronary syndromes. We aimed to establish the association between NT-proBNP and all-cause mortality in patients with stable chronic coronary heart disease. Three-hundred-eighty-five patients, 6–24 months after acute coronary syndrome or coronary revascularisation, but without history or symptoms of chronic heart failure, were included into the cohort study. The NT-proBNP was measured at baseline and all-cause mortality was ascertained after more than 6 years of follow-up. Patients with NT-proBNP above 862 pmol/l (i.e. in top quintile) showed significantly higher mortality rates, than patients with lower NT-proBNP; the adjusted odds ratio (and 95% confidence intervals) for all-cause death was in patients with NT-proBNP >862 pmol/l 3.26 (1.40–7.62). In conclusion, the asymptomatic elevation of NT-proBNP provides prognostic information also in stable coronary patients not yet manifesting any symptoms of heart failure.
Similar content being viewed by others
Abbreviations
- ACS:
-
Acute coronary syndrome
- BNP:
-
Brain natriuretic peptide
- CHD:
-
Coronary heart disease
- CHF:
-
Congestive heart failure
- GLU:
-
Glucose
- HDL:
-
High-density lipoprotein cholesterol
- NT-proBNP:
-
N-terminal fragment of brain natriuretic peptide
- NYHA:
-
New York Heart Association classification
- RF:
-
Risk factor
- TCHOL:
-
Total cholesterol
- TG:
-
Triglycerides
- tHcy:
-
Total homocysteine
References
Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–8. doi:10.1056/NEJM199807303390507.
Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail. 2004;6:257–60. doi:10.1016/j.ejheart.2003.12.015.
Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J. 2003;17:1105–7.
Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J. 2003;24:1735–43. doi:10.1016/j.ehj.2003.07.005.
Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the carvedilol prospective randomized cumulative survival (COPERNICUS) trial. Circulation. 2004;110:1780–6. doi:10.1161/01.CIR.0000143059.68996.A7.
James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a global utilization of strategies to open occluded arteries (GUSTO)-IV substudy. Circulation. 2003;108:275–81. doi:10.1161/01.CIR.0000079170.10579.DC.
de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014–21. doi:10.1056/NEJMoa011053.
Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, et al. Australia-New Zealand Heart Failure Group. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol. 2001;37:1781–7. doi:10.1016/S0735-1097(01)01269-4.
Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352:666–75. doi:10.1056/NEJMoa042330.
Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655–63. doi:10.1056/NEJMoa031994.
EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Eur Heart J. 2001;22:554–72. doi:10.1053/euhj.2001.2610.
Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin Chem. 2003;49:976–9. doi:10.1373/49.6.976.
Omland T, Persson A, Ng L, O’Brien R, Karlsson T, Herlitz J, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002;106:2913–8. doi:10.1161/01.CIR.0000041661.63285.AE.
Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart. 2004;90:297–303. doi:10.1136/hrt.2003.026021.
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. INTERHEART Study investigators: effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52. doi:10.1016/S0140-6736(04)17018-9.
Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, et al. HOPE study investigators. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the heart outcomes prevention evaluation (HOPE) study. Circulation. 2006;114:201–8. doi:10.1161/CIRCULATIONAHA.105.590927.
De Bacquer D, De Backer G, Ostor E, Simon J, Pyorala K. EUROASPIRE I Study Group.Predictive value of classical risk factors and their control in coronary patients: a follow-up of the EUROASPIRE I cohort. Eur J Cardiovasc Prev Rehabil. 2003;10:289–95. doi:10.1097/00149831-200308000-00012.
Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. REACH Registry Investigators International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–9. doi:10.1001/jama.295.2.180.
Miller WL, Skouri HN. Chronic systolic heart failure, guideline-directed medical therapy, and systemic hypotension-less pressure but maybe more risk (does this clinical scenario need more discussion?). J Card Fail. 2009;15:101–7. doi:10.1016/j.cardfail.2008.07.228.
Acknowledgments
The present study was funded by Internal Grant Agency of Czech Ministry of Health (grant no. 9333-3) and by Ministry of Education (grant no. 0021620819). We also used several data from EUROASPIRE II survey, carried out under auspices of European Society of Cardiology. We would to acknowledge the cooperation of investigators who participated on the EUROASPIRE II survey.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mayer, O., Šimon, J., Plášková, M. et al. N-terminal pro B-type natriuretic peptide as prognostic marker for mortality in coronary patients without clinically manifest heart failure. Eur J Epidemiol 24, 363–368 (2009). https://doi.org/10.1007/s10654-009-9339-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10654-009-9339-6